PepGen, Inc. (NASDAQ:PEPG) Receives Consensus Rating of “Hold” from Analysts

PepGen, Inc. (NASDAQ:PEPG) has earned a consensus recommendation of “Hold” from the six analysts that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $8.40.

A number of analysts have recently weighed in on PEPG shares. Weiss Ratings restated a “sell (d-)” rating on shares of PepGen in a research note on Wednesday, October 8th. Stifel Nicolaus boosted their price objective on shares of PepGen from $9.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Wedbush boosted their price objective on shares of PepGen from $7.00 to $9.00 and gave the stock an “outperform” rating in a research note on Thursday, September 25th. HC Wainwright boosted their price objective on shares of PepGen from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Finally, Guggenheim restated a “buy” rating and issued a $6.00 price objective on shares of PepGen in a research note on Wednesday, September 24th.

Insider Transactions at PepGen

In related news, major shareholder Science Enterprises Plc Oxford bought 200,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 30th. The shares were acquired at an average price of $3.20 per share, with a total value of $640,000.00. Following the completion of the transaction, the insider owned 4,955,388 shares of the company’s stock, valued at $15,857,241.60. The trade was a 4.21% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On PepGen

Institutional investors and hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd bought a new position in PepGen during the first quarter worth $25,000. ADAR1 Capital Management LLC bought a new position in PepGen during the first quarter worth $29,000. Rangeley Capital LLC increased its position in PepGen by 133.3% during the second quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock worth $39,000 after acquiring an additional 20,000 shares during the period. Marshall Wace LLP bought a new position in PepGen during the second quarter worth $44,000. Finally, Qube Research & Technologies Ltd bought a new position in PepGen during the second quarter worth $81,000. Institutional investors own 58.01% of the company’s stock.

PepGen Stock Performance

Shares of PEPG opened at $4.89 on Monday. The firm has a market cap of $160.39 million, a PE ratio of -1.65 and a beta of 1.96. The firm’s 50 day moving average price is $2.62 and its 200 day moving average price is $1.81. PepGen has a twelve month low of $0.88 and a twelve month high of $9.15.

PepGen (NASDAQ:PEPG) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.15. On average, sell-side analysts anticipate that PepGen will post -2.73 earnings per share for the current fiscal year.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.